342017-95-2

Usage

Uses

Used in Pharmaceutical Industry:
6-BROMO-2-(4-BROMO-PHENYL)-QUINOLINE-4-CARBOXYLIC ACID serves as a starting material for the synthesis of various biologically active compounds, contributing to the development of new drugs with potential therapeutic applications.
Used in Chemical Industry:
In the chemical industry, 6-BROMO-2-(4-BROMO-PHENYL)-QUINOLINE-4-CARBOXYLIC ACID is utilized for its unique reactivity and structural features, acting as a valuable intermediate in the synthesis of complex organic molecules, which can be further modified for specific applications.
Used in Medicinal Chemistry Research:
6-BROMO-2-(4-BROMO-PHENYL)-QUINOLINE-4-CARBOXYLIC ACID is employed in medicinal chemistry research as a potential drug candidate or as a building block in drug discovery. Its distinctive structure allows for exploration in the creation of novel therapeutic agents.

Upstream product

• 87-48-9 5-Bromo-1H-indole-2,3-dione 
• 99-90-1 para-bromoacetophenone 
• 98-86-2 acetophenone 

Relevant academic research and scientific papers

Synthesis, characterization, and antileishmanial activity of certain quinoline-4-carboxylic acids

Leishmaniasis is a fatal neglected parasitic disease caused by protozoa of the genus Leishmania and transmitted to humans by different species of phlebotomine sandflies. The disease incidence continues to increase due to lack of vaccines and prophylactic drugs. Drugs commonly used for the treatment are frequently toxic and highly expensive. The problem of these drugs is further complicated by the development of resistance. Thus, there is an urgent need to develop new antileishmanial drug candidates. The aim of this study was to synthesize certain quinoline-4-carboxylic acids, confirm their chemical structures, and evaluate their antileishmanial activity. Pfitzinger reaction was employed to synthesize fifteen quinoline-4-carboxylic acids (Q1-Q15) by reacting equimolar mixtures of isatin derivatives and appropriate α-methyl ketone. The products were purified, and their respective chemical structures were deduced using various spectral tools (IR, MS, 1H NMR, and 13C NMR). Then, they were investigated against L. donovani promastigote (clinical isolate) in different concentration levels (200 μg/mL to 1.56 μg/mL) against sodium stibogluconate and amphotericin B as positive controls. The IC50 for each compound was determined and manipulated statistically. Among these compounds, Q1 (2-methylquinoline-4-carboxylic acid) was found to be the most active in terms of IC50.

A series of quinoline analogues as potent inhibitors of C. albicans prolyl tRNA synthetase

A series of quinoline inhibitors of C. albicans prolyl tRNA synthetase was identified. The most potent analogue, 2-(4bromo-phenyl)-6-chloro-8-methyl-4-quinolinecarboxylic acid, showed IC50=5 nM (Ca. ProRS) with high selectivity over the human enzyme.